GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Tonix Pharmaceuticals
Shares of Tonix, a biopharmaceutical company with a broad and diverse pipeline, are extremely volatile. Their price is driven not by stable earnings, but by a constant stream of news about various clinical programs, which attracts speculative interest.
Share prices of companies in the market segment - Pharma other
Tonix Pharmaceuticals (TNXP) is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, pain management, vaccines, and immunomodulators. We classify it as "Other Pharmaceuticals." The chart below shows the dynamics of the biotech sector with a broad development pipeline.
Broad Market Index - GURU.Markets
Tonix Pharmaceuticals is a biopharmaceutical company with a broad portfolio of developments in the fields of central nervous system diseases, immunology, and infectious diseases. Its diversification makes it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Tonix compares to it.
Change in the price of a company, segment, and market as a whole per day
TNXP - Daily change in the company's share price Tonix Pharmaceuticals
The daily price change of Tonix, a biopharmaceutical company with a broad portfolio, reflects the risks of early-stage development. Change_co measures the high volatility associated with news from various clinical programs. This metric is important for analyzing diversified but speculative biotechs on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma other
Tonix Pharmaceuticals Holding Corp. is a biotech company. This chart demonstrates the sector's extreme volatility. Comparison with TNXP's performance, with its broad but risky development pipeline, helps to appreciate its speculative nature.
Daily change in the price of a broad market stock, index - GURU.Markets
Tonix is a biopharmaceutical company developing drugs to treat various diseases. The biotech sector is known for its high volatility. The chart below shows average daily fluctuations in the industry, allowing one to assess how Tonix's performance aligns with overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Tonix Pharmaceuticals
Tonix Pharmaceuticals' year-to-date performance reflects a diversified clinical-stage pipeline. Its 12-month market cap is highly volatile and dependent on developments across its programs, from post-traumatic stress disorder to vaccines. Any success or failure in any one area dramatically impacts its valuation.
Annual dynamics of market capitalization of the market segment - Pharma other
Tonix Pharmaceuticals Holding Corp. is a biotech company with a diversified pipeline. Its stock price is highly volatile, reflecting both the risks and potential of its numerous early-stage projects, making it a speculative bet compared to the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tonix is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Tonix Pharmaceuticals
The price of Tonix, a biopharmaceutical company, is highly volatile. Monthly fluctuations reflect news about its numerous and diverse clinical programs in the CNS and immunology fields, creating a constant stream of potential catalysts, but also high uncertainty.
Monthly dynamics of market capitalization of the market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a broad pipeline of developments targeting central nervous system disorders, immunology, and infectious diseases. The chart below reflects the overall dynamics of the diversified pharmaceutical sector, where investors are evaluating a variety of "shots on target."
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tonix Pharmaceuticals Holding Corp. is a biotechnology company with a broad development pipeline. Its shares are highly volatile and move based on news about various clinical programs. Due to its speculative nature and ongoing need for funding, the company's performance is unrelated to overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Tonix Pharmaceuticals
Shares of Tonix Pharmaceuticals, a biopharmaceutical company with a broad pipeline of developments, are highly volatile. Weekly price movements reflect news of numerous clinical trials in various areas, from the central nervous system to vaccines. The chart below shows how short-term announcements in any area can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma other
How does Tonix Pharmaceuticals' performance compare to the broader pharmaceutical sector? The chart below compares the company's weekly stock price movements with its diversified pipeline to the industry average. This helps us understand how the multitude of potential news triggers creates unique and high volatility compared to more focused companies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Tonix Pharmaceuticals is a biotech company with a broad, yet early-stage, pipeline. This chart compares its speculative and volatile weekly performance to the market to show how much its stock is driven by news about numerous studies rather than by general trends.
Market capitalization of the company, segment and market as a whole
TNXP - Market capitalization of the company Tonix Pharmaceuticals
Tonix Pharmaceuticals' price chart exemplifies the high volatility of micro-cap biotechs. Its valuation depends on news from a broad, yet early, pipeline of developments in various fields. Its dynamics reflect the speculative nature of investing in companies with multiple "lottery tickets."
TNXP - Share of the company's market capitalization Tonix Pharmaceuticals within the market segment - Pharma other
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company whose market share reflects its diversified but high-risk pipeline of developments in areas ranging from post-traumatic stress disorder to vaccines.
Market capitalization of the market segment - Pharma other
The chart illustrates the aggregate market capitalization of small biotech companies with a broad development portfolio. Tonix Pharmaceuticals is an example of such a diversified model. The graph shows how the market values a sector where companies attempt to mitigate risk by working on multiple projects simultaneously.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes the market value of a biotech company working on a wide range of diseases. Tonix Pharmaceuticals' market cap reflects its diverse development portfolio, from PTSD to vaccines. The line illustrates the risks and potential of a diversified strategy in the pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
TNXP - Book value capitalization of the company Tonix Pharmaceuticals
The chart below shows the scientific foundation of Tonix Pharmaceuticals. Its line reflects the value of its broad and diversified intellectual property portfolio covering drugs for the treatment of central nervous system disorders, immunology, and infectious diseases. The dynamics reflect the company's clinical research activity in many areas.
TNXP - Share of the company's book capitalization Tonix Pharmaceuticals within the market segment - Pharma other
For Tonix Pharmaceuticals, a company with a broad development portfolio, its tangible assets are its R&D centers and laboratories. The chart shows the company's share of physical infrastructure, which serves as a springboard for research in various fields, from pain management to biodefense.
Market segment balance sheet capitalization - Pharma other
Below you can see the overall book value of the pharmaceutical sector. Against this backdrop, Tonix, with its broad and diversified development portfolio, looks like a classic R&D company. Its balance sheet is "light," as its strategy is to advance multiple projects through the clinical stages rather than build factories.
Book value of all companies included in the broad market index - GURU.Markets
Tonix Pharmaceuticals develops a portfolio of drugs for the central nervous system and immunology. The company's assets are not factories, but intellectual property and clinical trial data. The company's balance sheet is a diversified portfolio of "bets" on one of its molecules becoming a successful, life-changing drug.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Tonix Pharmaceuticals
Tonix's balance sheet consists of cash and a very broad portfolio of early-stage developments. Its market capitalization reflects the low probability of success for any of them. The MvsBCap_Co chart, close to one, shows that the market values the company almost like a "piggy bank," placing little value on its scientific "lottery tickets."
Market to book capitalization ratio in a market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a broad and diverse development pipeline. The chart shows the speculative valuation of its numerous projects. This valuation is highly volatile and depends on news about the progress of clinical trials in various areas.
Market to book capitalization ratio for the market as a whole
Tonix Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system, immunology, and infectious diseases. Its value is determined by its broad, yet risky, pipeline. This chart shows how the market values early-stage companies with a diversified pipeline.
Debts of the company, segment and market as a whole
TNXP - Company debts Tonix Pharmaceuticals
Tonix Pharmaceuticals' debt policy reflects its diversified development portfolio. This chart shows how the company raises capital to fund clinical trials in various areas, from post-traumatic stress disorder to vaccines. For a biotech company with a wide range of projects, debt is a way to diversify risk and increase the chances of success.
Market segment debts - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified portfolio of drug candidates for the treatment of central nervous system and immunology diseases. Managing multiple projects simultaneously requires significant resources. This chart shows how the company allocates capital and funds its numerous clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Tonix Pharmaceuticals
Tonix Pharmaceuticals develops drugs for the treatment of central nervous system and immunology diseases. This chart shows its financial dependence on debt. For a diversified pharmaceutical company still in the development stage, debt increases risks, as the failure of one of its key drugs could complicate debt servicing.
Market segment debt to market segment book capitalization - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a broad development portfolio in various fields, from the central nervous system to biodefense. It has a diversified, but risky, approach. The chart shows how the company's debt load, used to finance multiple projects, compares to its overall market capitalization and the risks associated with the pharmaceutical industry.
Debt to book value of all companies in the market
#VALUE!
P/E of the company, segment and market as a whole
P/E - Tonix Pharmaceuticals
For Tonix Pharmaceuticals, a biotech company with a very broad and diverse pipeline, this chart reflects a high degree of risk. There is no P/E ratio. The company's valuation is spread across numerous early-stage projects, making it difficult for investors to assess the likelihood of success for any one of them.
P/E of the market segment - Pharma other
This chart shows the average valuation for biopharmaceutical companies. For Tonix, with its very broad development portfolio, this is an interesting benchmark. It helps us understand the average valuation of companies in the sector and the discount the market might be offering Tonix for its fragmented and difficult-to-analyze strategy.
P/E of the market as a whole
Tonix Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders, pain management, and immunology. The company's portfolio is diversified but still in the early stages. This chart, reflecting risk appetite, helps understand how investors value biotech companies with a broad but immature portfolio.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Tonix Pharmaceuticals
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified pipeline of candidates in various fields, including central nervous system diseases, immunology, and infectious diseases. This chart reflects expectations for its numerous early-stage developments. The score is a composite of the probabilities of success in each of its research areas.
%20P%2FE%20Tonix%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Tonix-Pharmaceuticals&v=1772632336584 "Chart of the company's future (projected) P/E Tonix Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified pipeline of developments in the fields of central nervous system (CNS), immunology, and infectious diseases. This chart reflects the company's long-term profitability expectations. It shows how the market assesses the likelihood of success for at least one of its many early-stage projects.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772632336598 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Tonix Pharmaceuticals is a biopharmaceutical company with a broad development pipeline, ranging from biodefense to CNS drugs. Its value consists of options on the success of numerous projects. This market expectations curve influences Tonix through investors' overall risk appetite and their willingness to fund early-stage biotech companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772632336634 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Tonix Pharmaceuticals
Tonix Pharmaceuticals is a biopharmaceutical company with a broad pipeline of developments in the fields of central nervous system diseases, immunology, and infectious diseases. The company is in the clinical stage. Its financial performance reflects the expenditures on multiple research programs.
Profit of companies in the market segment - Pharma other
Tonix Pharmaceuticals develops drugs for the treatment of central nervous system and immunology disorders. The company's portfolio is diversified but still in the early stages. This chart for the biotech sector illustrates how companies with broad but immature R&D portfolios represent a set of options for future success, impacting the overall risk profile.
Overall market profit
Tonix Pharmaceuticals is a biopharmaceutical company with a broad pipeline of developments in various fields, from the central nervous system to immunology. Being in clinical trials, its value is determined by news about the progress of trials and the potential of its drugs. This dynamic is independent of general economic trends, which can be seen on this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Tonix Pharmaceuticals
Tonix Pharmaceuticals is a biotech company with a diversified pipeline targeting central nervous system diseases and immunology. This graph reflects expectations, which depend on clinical trial success in multiple areas. The lack of focus on a single area makes forecasting more challenging.
%20profit%20of%20the%20company%20Tonix%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Tonix-Pharmaceuticals&v=1772632336793 "Graph of future (projected) profit of the company Tonix Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified development portfolio focused on diseases of the central nervous system and immunology. This chart shows the revenue forecast for the entire pharmaceutical sector. It reflects the overall expectations for clinical trial success, which is a key benchmark for evaluating Tonix's numerous programs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772632336827 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified development portfolio across various fields. Its value depends on the success of clinical trials. The overall economic situation, reflected in this chart, influences its performance through the availability of capital and the overall sentiment in the biotech market, which determine its ability to finance its numerous projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772632336848 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Tonix Pharmaceuticals
Tonix Pharmaceuticals is a biopharmaceutical company with a broad and diverse pipeline of drug candidates in areas ranging from post-traumatic stress disorder to vaccines. This chart reflects how investors view its diversified yet risky approach, where the success of even one product can lead to significant revenue growth.
P/S market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company developing drugs to treat central nervous system (CNS) disorders such as fibromyalgia and post-traumatic stress disorder (PTSD). This chart shows the average valuation for the sector, helping to understand how the market views Tonix's clinical development pipeline and product candidates.
P/S of the market as a whole
Tonix Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders and vaccines. The company's portfolio is diversified but still in the early stages. This market valuation chart helps understand how investors view the biotech company with a broad but risky pipeline.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Tonix Pharmaceuticals
Tonix Pharmaceuticals is a biopharmaceutical company with a broad pipeline. Its valuation depends on the success of numerous clinical programs in various fields. This chart reflects investors' aggregate expectations for the entire pipeline of candidates and the likelihood of commercialization of at least some of them.
%20P%2FS%20Tonix%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Tonix-Pharmaceuticals&v=1772632336978 "The graph of the company's future (projected) P/S Tonix Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified pipeline of candidates in the fields of central nervous system, immunology, and infectious diseases. This chart compares market expectations for its future revenue with those of other pharmaceutical companies. The valuation reflects speculative investor expectations for its numerous clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772632337018 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Tonix Pharmaceuticals is a biotech company with a broad pipeline. Its success depends on successful clinical trials. As with many companies in this sector, the overall market optimism reflected in this chart is critical, as it ensures access to the funding needed to continue expensive research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772632337053 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Tonix Pharmaceuticals
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified portfolio of drug candidates targeting diseases of the central nervous system and immunology. While in development, its revenue, when any, comes from grants or partnerships. The chart shows the financial flows that support its numerous clinical programs.
Sales of companies in the market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified pipeline targeting central nervous system disorders, rare diseases, and biodefense. The company currently has no commercial products and is funded by investors. This chart reflects the state of the biotech sector, where companies with a broad portfolio are raising capital for various programs.
Overall market sales
Tonix Pharmaceuticals is a biopharmaceutical company with a broad pipeline of developments in various fields. Being in the clinical stage, its value depends on research news rather than economic cycles. However, this timeframe influences overall market sentiment, which impacts the company's ability to attract funding for its numerous programs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Tonix Pharmaceuticals
Tonix Pharmaceuticals is a biopharmaceutical company with a broad and diverse pipeline of drug candidates in various fields, including the central nervous system, immunology, and infectious diseases. This chart reflects analysts' average and speculative expectations for the success of at least one of the company's numerous programs in development.
%20sales%20of%20the%20company%20Tonix%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Tonix-Pharmaceuticals&v=1772632337127 "Schedule of future (projected) sales of the company Tonix Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified pipeline of developments in the fields of central nervous system diseases, immunology, and infectious diseases. This chart shows the overall outlook for the pharmaceutical industry. It allows one to assess how the company is managing its broad, yet early-stage, pipeline and its chances of success.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772632337153 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Tonix Pharmaceuticals is a biopharmaceutical company developing drugs for the central nervous system and immunology. This chart, reflecting the biotech investment climate, is important for the company in the development stage. The ability to raise capital for clinical trials is directly dependent on overall investor sentiment and the state of financial markets.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772632337173 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Tonix Pharmaceuticals
Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on diseases of the central nervous system and immunology. Its pipeline is in development, requiring significant funding. This chart shows the current investment phase, when the company is spending funds on research to develop future commercial products.
Market segment marginality - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified pipeline of developments in the fields of central nervous system diseases, immunology, and infectious diseases. This broad pipeline requires significant investment. This chart shows how the company allocates its resources across various programs, which impacts its overall operating expense structure.
Market marginality as a whole
Tonix Pharmaceuticals is a biotech company with a very broad and diversified development portfolio. Unlike focused biotechs, they operate in many areas, from vaccines to psychiatry. Overall profitability is irrelevant to them. Their strategy is risk diversification, but this also spreads their resources thin.
Employees in the company, segment and market as a whole
Number of employees in the company Tonix Pharmaceuticals
Tonix Pharmaceuticals is a biotech company with a broad and diversified development portfolio across various fields. This graph shows the team working on a variety of projects. Headcount dynamics reflect activity across various clinical programs, from CNS to biodefense.
Share of the company's employees Tonix Pharmaceuticals within the market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system and immunology disorders. This chart shows its market share in the pharmaceutical sector. It reflects the breadth of its research portfolio and the team of scientists working on new treatments for various diseases.
Number of employees in the market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified pipeline of developments in the fields of central nervous system diseases, immunology, and infectious diseases. This chart illustrates its activity in the pharmaceutical sector. The dynamics reflect the company's clinical trial activity across various areas, which is typical for companies with a broad pipeline.
Number of employees in the market as a whole
Tonix Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system diseases, as well as vaccines. Its diversified portfolio requires a wide range of specialists. This chart shows the overall labor market, where pharmaceutical companies like Tonix make a significant contribution by creating jobs in research, development, and manufacturing.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Tonix Pharmaceuticals (TNXP)
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company operating in several therapeutic areas. During the development stage, its value is determined by its pipeline of potential drugs. This chart shows a high but volatile market capitalization per employee, as the market evaluates the likelihood of clinical trial success. It is a classic example of an R&D-driven biotech business.
%20of%20the%20company%20Tonix%20Pharmaceuticals%20(TNXP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Tonix-Pharmaceuticals-TNXP&v=1772632337594 "Chart of market capitalization per employee (in thousands of dollars) of the company Tonix Pharmaceuticals (TNXP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Tonix Pharmaceuticals is a biopharmaceutical company with a broad pipeline of developments in the fields of the central nervous system, immunology, and infectious diseases. For a company with a diversified R&D team, this metric reflects the overall market assessment of all its projects. The chart provides insight into the market's confidence in the team's ability to bring at least one of its drugs to commercial success.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772632337598 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Tonix Pharmaceuticals is a biopharmaceutical company with a broad and diverse pipeline, ranging from CNS drugs to vaccines. This chart will reflect the aggregate, albeit risky, market valuation of all their projects. The per-employee value will indicate how much investors believe in the team's ability to bring at least part of this pipeline to success.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772632337626 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Tonix Pharmaceuticals (TNXP)
Tonix Pharmaceuticals (TNXP) is a biopharmaceutical company with a broad but early-stage pipeline (CNS, immunology). This chart shows how the company manages its R&D budget. It measures the negative return (expense) per employee, reflecting how efficiently (or inefficiently) the company allocates capital across multiple research projects.
%20Chart%20Tonix%20Pharmaceuticals%20(TNXP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Tonix-Pharmaceuticals-TNXP&v=1772632337650 "Company Profit Per Employee (in thousands of dollars) Chart Tonix Pharmaceuticals (TNXP)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Tonix Pharmaceuticals is a diversified biopharmaceutical company focused on CNS therapeutics, vaccines, and immunomodulators. This chart shows the benchmark for biotech staff efficiency. It helps assess how effectively (or disproportionately) Tonix's team utilizes investor capital compared to its competitors.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772632337667 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Tonix Pharmaceuticals is a biopharmaceutical company with a broad and diverse pipeline, ranging from post-traumatic stress treatments to vaccines. Because of this diversification, this chart shows the total R&D expenditures per employee across multiple projects. This reflects the company's strategy of "spreading the bets" in the hopes that one project will succeed.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772632337704 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Tonix Pharmaceuticals (TNXP)
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified pipeline. This chart reflects its business model. Low or irregular revenue per employee is typical for companies whose income depends on partnerships and grants and whose primary focus is advancing multiple candidates through clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Tonix-Pharmaceuticals-TNXP&v=1772632337728 "Sales chart per company employee Tonix Pharmaceuticals (TNXP)")
Sales per employee in the market segment - Pharma other
Tonix Pharmaceuticals (TNXP) is a biotech company with a diversified development portfolio focused on central nervous system diseases (e.g., fibromyalgia) and immunology. This chart shows how much revenue (from partnerships) each employee (scientist) generates. This is an indicator of the productivity of their R&D platform.
Sales per employee for the market as a whole
Tonix Pharmaceuticals is a biotech company with a highly diversified portfolio, working on CNS drugs and vaccines. The company is in the clinical stage. This graph (close to zero) reflects their R&D model: their research staff is working on numerous projects, but the company does not yet have stable commercial revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Tonix Pharmaceuticals (TNXP)
Tonix Pharmaceuticals is a biotech company with a very broad and diverse pipeline (from fibromyalgia to vaccines). This chart shows bearish bets. Shorts are often driven by the company's lack of focus, failures in trials, and constant reverse splits, diluting investors' stakes.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Tonix-Pharmaceuticals-TNXP&v=1772632337805 "Short Shares Chart for the Company Tonix Pharmaceuticals (TNXP)")
Shares shorted by market segment - Pharma other
Tonix Pharmaceuticals (TNXP) is a biopharmaceutical company with a very broad and diversified pipeline, ranging from fibromyalgia to vaccines. This chart shows bets against the entire biotech sector. The rising bets against the industry reflect investor skepticism toward companies with diffuse focus that burn cash without a clear flagship product.
Shares shorted by the overall market
Tonix Pharmaceuticals (TNXP) is a biotech with a highly diversified but early-stage portfolio (CNS, vaccines). It's a speculative stock that frequently issues additional shares. This market fear chart shows when investors are fleeing risky assets. For TNXP, panic means difficulties raising new capital for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Tonix Pharmaceuticals (TNXP)
Tonix Pharmaceuticals is a speculative biotech with a very broad and constantly changing portfolio (from fibromyalgia to vaccines). This chart measures how investors react to this news flow. It shows when the stock is "overbought" on the announcement of a new project or "oversold" on news of another failure.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Tonix-Pharmaceuticals-TNXP&v=1772632337857 "RSI 14 indicator chart for the company's stock Tonix Pharmaceuticals (TNXP)")
RSI 14 Market Segment - Pharma other
Tonix Pharmaceuticals is a biotech company with a diversified development portfolio, including CNS drugs (fibromyalgia), vaccines, and biodefense products. This chart measures the overall momentum in the biotech sector. It helps determine whether the entire speculative segment is oversold based on clinical data.
RSI 14 for the overall market
Tonix Pharmaceuticals, a biotech company, depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like TNXP are forced to struggle to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TNXP (Tonix Pharmaceuticals)
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified pipeline, including CNS (fibromyalgia) and biodefense (vaccines) treatments. This chart shows the average target price. Analysts assess the likelihood of success of the most advanced clinical programs and their market potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TNXP-Tonix-Pharmaceuticals&v=1772632337910 "A chart showing analyst consensus forecasts for the expected stock price. TNXP (Tonix Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price TNXP (Tonix Pharmaceuticals)
Tonix (TNXP) is a biopharmaceutical lottery player that is trying to develop drugs for a variety of diseases (CNS, biodefense, COVID), often with failures. This chart shows their reversal rate. It measures the gap between the price and the consensus target, reflecting whether analysts believe (or even believe) in any of their numerous R&D projects.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TNXP-Tonix-Pharmaceuticals&v=1772632337926 "A chart showing the difference between the consensus forecast and the actual stock price. TNXP (Tonix Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Tonix Pharmaceuticals (TNXP) is a biopharmaceutical company with a broad but speculative R&D pipeline, including drugs for the central nervous system, vaccines, and immunology. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe in "broad-based" R&D strategies.
Analysts' consensus forecast for the overall market share price
Tonix Pharmaceuticals is a biopharmaceutical company with a diversified development portfolio, specializing in drugs for the central nervous system, immunology, and infectious diseases. This chart shows the overall "risk appetite." For Tonix, as a clinical-stage company with multiple projects, overall market optimism (an upward trend in the chart) is important for raising capital for all funding areas.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Tonix Pharmaceuticals
Tonix Pharmaceuticals (TNXP) is a biotech company with a very broad, yet risky, R&D pipeline. They're working on everything from fibromyalgia and long-term COVID-19 to biodefense (vaccines). This chart is a summary indicator of their lottery tickets. Its dynamics are extremely volatile and reflect news (often negative) from their numerous and disparate clinical trials.
AKIMA Market Segment Index - Pharma other
Tonix Pharmaceuticals develops drugs for the treatment of central nervous system disorders (such as fibromyalgia) and works in biosecurity. This chart shows the average index for the pharmaceutical sector. It helps investors assess how effective or risky Tonix's diversified portfolio is compared to the average pharmaceutical company.
The AKIM Index for the overall market
Tonix Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of central nervous system disorders (fibromyalgia, PTSD) and immunology. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story with a broad pipeline compares to overall economic trends and volatility.
